2019 Cannabis Business Award's Publication of the Year |
WEDNESDAY, DECEMBER 3, 2025 |
FMCPG HAS BEEN SERVING AND REPRESENTING THE CANNABIS PHYSICIAN COMMUNITY
SINCE 2020 |
THE "FLORIDA MEDICAL CANNABIS PHYSICIAN GROUP" (FMCPG)
FOR ALL "MEDICAL MARIJUANA DOCTORS" AND "MMTC DIRECTORS ONLY " SPECIAL GUEST: JODI JAMES - FL CAN UPDATE FROM TALLAHASSEE
ROBERT FRIEDMAN - CLAB MICHAEL BARENBOYM - WEEDGETS DISCUSS AND UPDATE THE LEGISLATIVE PRIORITIES FOR
2025/2026
REVIEW OF THE OMMU AND CHANGES TO THE DOCTOR'S AND PATIENT INPUT PORTALS ON THE OMMU WEBSITE.
DOCTORS WITHIN OUR GROUP WILL DISCUSS HOW THEY HAVE BEEN WORKING AROUND SOME OF THE CHANGES
REF'S ISSUES AND SOLUTIONS
TIME TO RENEW YOUR MEMBER IN FMCPG
CLICK HERE FOR THE MEMBERSHIP FORM USE THIS LINK TO REGISTER FOR THE NEXT MEETING - WEDNESDAY, DECEMBER 10, 2025 CLICK ON LINK BELOW |
MEDICAL CANNABIS PHYSICIAN PROMOTION PACKAGE FOR 2026 BY CANNABIS NEWS FLORIDA
ARTICLE: Physician will contribute an article of 350 words**. This article will appear in the Cannabis News Florida e-newsletter for one month (4 weeks).
E-MAIL BLAST: Cannabis News Florida will send out one e-mail blast promoting the Physician to the other physicians in three zip code areas or one city to be determined by the Physician. The Physician will supply the information for the email blast. The Article above can be used in the e-mail blast.
The cost of this program is ONLY $399 AND INCLUDES A ONE YEAR MEMBERSHIP IN THE FMCPG - MUST BE PUCHASED BEFORE 12/31/25 **Cannabis News Florida will assign a writer for a telephone interview with the Physician and create the article to be published. Physician shall have the right to review and approve the article before publication for an additional cost of $100. IF YOU ARE INTERESTED, PLEASE EMAIL ME AT CHARLES@CANNABISNEWSFLORIDA.COM OR CALL MY CELL AT 954-605-4785 |
Why Weedgets Smoking Products Are Better for Your Lungs
When it comes to smoking, your lungs deserve protection—and that’s exactly what Weedgets products are designed to deliver. Unlike traditional pipes or joints that expose you to hot smoke and harsh particulates, Weedgets offers a cleaner, smoother, and safer smoking experience engineered for your respiratory health. Advanced Filtration for Cleaner Smoke At the heart of every Weedgets innovation is filtration technology. Weedgets pipes and accessories feature integrated micro-filters that trap impurities and resin particles before they reach your lungs. This significantly reduces exposure to tar, ash, and other combustion byproducts that can irritate your airways and cause coughing. The result is a noticeably cleaner inhale that feels light yet delivers full flavor and potency. Cooling the Smoke to Protect Your Airways
One of the biggest threats to lung comfort is the temperature of the smoke itself. Hot, unfiltered smoke can inflame the delicate tissue lining your respiratory tract. Weedgets addresses this with cooling pathways and diffusion systems that lower smoke temperature before it enters your mouth. By cooling each puff, these devices minimize throat burn and lung irritation, letting you enjoy a smoother and more comfortable session.
Designed for Moisture Retention and Hydration
Traditional smoking dries out your throat and lungs, often leading to post-session irritation. Weedgets’ designs—including the award-winning MAZE-X pipe—use moisture-preserving features that maintain a more balanced humidity level in each draw. This helps reduce dryness and supports the lungs’ natural ability to stay hydrated and clear.
Less Coughing, More Breathing Comfort Many users notice that Weedgets devices help them cough less and breathe more comfortably. That’s because the filtered and cooled smoke allows for deeper, more natural inhales without the harsh hit. Whether you’re a daily smoker or someone who values occasional sessions, Weedgets technology helps you enjoy the benefits of cannabis while protecting your respiratory wellness. Sustainable and Hygienic Design
Weedgets products are built for cleanability and reusability, unlike disposable filters or cheap pipes that accumulate residue and bacteria. Each component can be easily cleaned, ensuring a fresh and sanitary smoking experience every time. This not only supports better lung health but also contributes to a cleaner environment. Science-Driven Innovation Developed by engineers and health-conscious designers, Weedgets represents the future of responsible smoking. Every product is tested and refined to reduce the harmful effects of smoke inhalation while preserving the full sensory and therapeutic experience of cannabis.
In summary: Weedgets isn’t just about better smoking—it’s about smarter smoking. By filtering, cooling, and cleaning each puff, Weedgets protects your lungs so you can enjoy cannabis safely, comfortably, and consciously.
CLICK HERE FOR MORE INFORMATION |
NEWS FROM THE PAST WEEK RELATING TO THE BUSINESS OF
MMTC'S IN FLORIDA Click on Company Logo to be Transferred to Web Site |
Trulieve Rewards
Trulieve Rewards is a customer rewards program offering patients and customers in participating states an easy platform to earn points on every purchase at Trulieve dispensaries. We've revamped and refreshed our old cannabis loyalty program to reward cannabis enthusiasts loyal to Trulieve with savings, perks, and points every time they shop for cannabis products JOIN NOW |
The Cannabist Company Announces Agreement for the Sale of Virginia Assets to Curaleaf
Dec. 2, 2025– The Cannabist Company Holdings Inc. (Cboe CA: CBST) (OTCQB: CBSTF) (“The Cannabist Company” or the “Company”), one of the most experienced cultivators, manufacturers and retailers of cannabis products in the U.S., today announced that it has entered into an agreement to sell all of the ownership interests of its subsidiary engaged in the business of cultivating, producing, manufacturing, distributing and selling cannabis in the Commonwealth of Virginia to a subsidiary of Curaleaf Holdings Inc. (the “Transaction”) for total consideration of $110 million, subject to adjustment. The assets consist primarily of 5 active retail locations, 1 additional retail location in development, and approximately 82,000 square feet of cultivation and production capacity in the Richmond region.
As previously announced, the Board of Directors of the Company formed a special committee of independent directors (the “Special Committee”) to review strategic alternatives. The Special Committee, with support from external financial and legal advisors, is considering a range of options, including potential asset sales, mergers, or other strategic or financial transactions. The review is being conducted in consideration of the ongoing operational and financial challenges for the Company and the industry, as well as of the continuing uncertainty as to if and when U.S. federal regulatory changes may occur that will impact the Company and the industry, including, without limitation, changes to U.S. federal taxation of the Company and the industry under Section 280(e) of the Internal Revenue Code. The Transaction forms part of this strategic review.
READ MORE |
The Cannabist Company and Old Pal Continue Successful Partnership with Expansion into West Virginia
Collaboration Brings Old Pal’s Signature Flower Products to a New Market
CHELMSFORD, Mass.–Nov. 26, 2025– The Cannabist Company (Cboe CA: CBST) (OTCQB: CBSTF) (“The Cannabist Company” or the “Company”), one of the most experienced cultivators, manufacturers and retailers of cannabis products in the U.S., announced today the expansion of its partnership with Old Pal, a top-performing cannabis brand rooted in simplicity, quality and value, with the introduction of Old Pal flower products to medical patients in West Virginia.
Building on the success of this collaboration in Maryland, Virginia, New Jersey and Colorado, The Cannabist Company launched Ground Flower (7 g, 14 g) and Whole Flower (3.5 g, 7 g) across all Cannabist locations in West Virginia. The launch arrives on November 26 and reflects the ongoing demand for high-quality flower offerings. All Old Pal products for West Virginia are cultivated and produced by The Cannabist Company in its state manufacturing facilities, with wholesale distribution expanding in December.
Old Pal first partnered with The Cannabist Company in 2023 with launches in Maryland and Virginia, followed by New Jersey in 2024 and the addition of Colorado later that year, where the Company also produces Old Pal-branded cannabis products. The brand’s debut in West Virginia marks its fifth market through the collaboration and continues the expansion of its flower product portfolio.
READ MORE |
Red White & Bloom Brands Files 2025-Q3 Interim Financial Statements
Dec. 01, 2025 — Red White & Bloom Brands Inc. (CSE: RWB) (“RWB” or the “Company”) announces that it has completed and filed its interim financial statements for the period ended September 30, 2025, together with the related management’s discussion and analysis and CEO and CFO certificates. Copies of these documents are available under the Company’s profile on SEDAR+ at www.sedarplus.ca.
The Company also announces that it has entered into a debt settlement agreement (the “Settlement Agreement”) with a former consultant of the Company, pursuant to which the Company will issue an aggregate of 375,000 common shares (the “Shares”) at the lesser of the CSE prescribed minimum price of $0.05 per Share and the twenty (20) day volume weighted average price per Share as of November 28, 2025 (on prior approval by the CSE), to settle certain outstanding obligations owed to the consultant for past services. The Company anticipates closing the debt settlement on or about December 8, 2025. Securities issued pursuant to the Settlement Agreement will be subject to a statutory hold period of four months and one day in accordance with applicable securities laws.
READ MORE |
FLUENT Reports Third Quarter 2025 Results
Focused on Margin Expansion, Operational Efficiency, and Strategic Market Positioning Ahead of Buffalo, New York and Rosa, Florida Premium Indoor Facility Activations in Q4 2025
TAMPA, Fla., Nov. 28, 2025 — FLUENT Corp. (CSE: FNT.U) (OTCQB: CNTMF) (“FLUENT” or the “Company”), a vertically-integrated, multi-state cannabis company, today announced its financial and operating results for the third quarter ended September 30, 2025. Unless otherwise indicated, all financial results are presented in U.S. dollars.
Management Commentary
“During the third quarter, we continued to execute on our strategic priorities with a clear focus on reversing the declining margin profile and enhancing operational efficiency across our footprint ahead of our new indoor capacity hitting retail shelves in the fourth quarter,” said Dave Vautrin, Interim CEO of FLUENT. “While consolidated revenue was relatively consistent year-over-year, we recognized pressure on gross margins driven by correcting extraction inefficiencies and a shifting product mix in Florida. We have already taken decisive actions to address these challenges, including optimizing our retail portfolio, improving distillate yields, accelerating product innovation, and bringing key indoor production facilities fully online.”
Vautrin continued, “We have also made disciplined investments during the current quarter in markets where we expect meaningful margin contribution. In Florida, we operationalized our large-scale Rosa indoor cultivation facility in November, nearly doubling our premium flower capacity. The Rosa facility is ramping up as planned and is now delivering true premium-quality flower and measurable improvements in yield, which we expect will support our objectives of achieving stronger margins through larger capture of the Florida premium market opportunity heading into 2026. In New York, we have operationalized our large-scale Buffalo premium indoor cultivation facility in Q4 2025 and are now preparing for the launch of premium SKUs from Connected and Alien Labs, which we believe will energize our efforts to improve our wholesale revenue and margin contribution. Across all markets, our near-term focus remains on optimizing operational excellence, capital efficiency, and driving sustainable margin expansion as we position FLUENT for long-term value creation.”
Q3 2025 Financial Highlights (vs. Q3 2024)
-Revenue: $26.0 million compared to $26.1 million in Q3 2024.
-Florida revenue: $21.6 million compared to $22.0 million in Q3 2024, reflecting pricing pressures.
-Gross profit before fair value adjustments1: $8.0 million (31% of revenue) compared to $14.3 million (54.6% of revenue) in Q3 2024.
-Adjusted EBITDA2: $2.8 million compared to $7.5 million in Q3 2024, primarily due to lower revenue and reduced margins.
-Cash flow from operations: Cash used in operations of $.8 million, compared to cash provided by operations of $9.5 million in Q3 2024.
-Balance sheet: On September 30, 2025, the Company had cash and cash equivalents of approximately $15.1 million and total debt outstanding of $72.2 million, compared to $8.9 million of cash and cash equivalents and $71.4 million in total debt outstanding on September 30, 2024. Common shares outstanding on an as-converted basis were approximately -714 million in Q3 2025 compared to 342 million common shares outstanding on an as-converted basis in Q3 2024.
READ MORE |
Viridian Capital Chart of the Week: Better Restructuring Outcomes Depend on Early Credit Problem Recognition
One of the panels that Viridian is moderating at the upcoming MjBiz conference addresses the future of cannabis restructurings, both pre- and post-rescheduling.
One point that nearly all parties can agree on is that restructuring efforts, whatever path they take, are more successful if action is taken before liquidity becomes critical or the firm’s resources are depleted.
The Viridian Chart of the Week shows the Viridian Credit Score (green line) for the 25 operators that we rank each week against another less robust indicator that investors should nevertheless be watching- total liabilities to market cap (purple line)
The Viridian Credit Model utilizes eleven financial and market variables to measure four primary credit factors: Liquidity, Leverage, Profitability, and Size. These factor scores are synthesized dynamically into an overall credit score shown on the graph. Total liabilities to market cap is one of four ratios we use to create our overall Leverage score.
We have been running and refining this model for almost 5 years, and it has shown both to correlate well with market trading levels of cannabis debt and to predict distress/restructuring. Followers of our research would have seen the deterioration of such credits as Lowell Farms, StateHouse, 4Front, AYR, Schwazze, and Gold Flora, in time to take protective actions. Our claim that “credit analysis is the new equity analysis” is only slightly overstated. In the current environment, growth is less important than the company’s clear survivability. If you are wrong on the credit analysis, your growth projections are meaningless.
The purple line depicts a much simpler indicator – total liabilities to market cap. Variations of this measure, usually employing total debt rather than total liabilities, have a rich history. These ratios are used in the bankruptcy prediction models of Merton and Altman, and they were used at Drexel Burnham in High-Yield bond analysis in the early days of the high-yield market. We choose to use total liabilities instead of total debt to capture the effects of operating leases and tax liabilities, both of which are critical.
The advantages of total liabilities to market cap are: Simple to calculate
Changes daily with respect to market price movements Can be shown to relate to asset value coverage of Liabilities through option price modeling
Investors should monitor this ratio over time. Is it just fluctuating with the market, or is it consistently moving in a particular direction?
We have established two warning levels for investors to note: when the ratio moves above 5x and above 10x. The 5x level typically coincides with an implied asset value coverage of 1x, so high levels indicate that creditors are beginning to take on equity risk. Meanwhile, the 10x level denotes significant credit impairment with asset values well below liabilities. The companies currently in the first warning zone include Ascend (7.77x), Jushi (6.40x), 1933 Industries (8.99x), and Fluent (8.37x). We want to be clear: numbers at this level do not scream imminent default, but they do put investors on notice. Check the liquidity and potential trigger events for these companies.
More serious issues are often signaled when companies pierce the 10x level. These companies included Cannabist (32.96x), Red White & Bloom (31.34x), Body & Mind (10.69x), Vibe (51.28x), and Tilt Holdings (69.82x). For most of these companies, the equity value damage has already been done, but investors exposed to the credit via debt positions or receivables need to Investors need not be surprised by credit issues. Monitoring the Viridian Credit ranking and total liabilities-to-market cap will often provide critical early warning signals. |
For More Analysis View This Week's Viridian Chart of the Week About Viridian Capital Advisors
Since launching in 2014, Viridian Capital Advisors has become one of the most respected and experienced advisory and M&A firms specializing in the cannabis industry. We provide a wide range of services, including: Strategic Advisory Consulting: Including valuation, financial modeling, restructuring and fairness opinions.
Mergers & Acquisitions: Transaction advisory and execution. Capital Raises: Including debt and equity. Many of our assignments begin with a basic question: "What should I do now?" Raise capital to expand? What kind of capital is most appropriate?
Acquire another company? What are the advantages and pitfalls?
Sell my company? What valuations can i achieve? What transaction structures are possible?
Put our experience, data and depth of senior talent behind your next transaction.
Contact
Scott Greiper
CEO
Viridian Capital Advisors, LLC
646.330.0704
sgreiper@viridianca.com
Frank Colombo
Managing Director
Viridian Capital Advisors, LLC
914.523.4730
fcolombo@viridianca.com
|
NATIONAL AND INTERNATIONAL NEWS |
PharmaTher Closes Sale of Ketamine ANDA, Sharpening Focus on Long-Acting Injectable Ketamine Franchise
December 2, 2025 – PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the “Company” or “PharmaTher”), a specialty life sciences company focused on unlocking the therapeutic potential of ketamine for neuropsychiatric disorders, today announced it has closed the previously announced sale of its Abbreviated New Drug Application (ANDA #217858) for Ketamine Hydrochloride Injection USP to a leading sterile-injectables pharmaceutical company.
At closing, PharmaTher received a confidential upfront cash payment and remains eligible to receive additional milestone payments based on cumulative sales thresholds, as well as profit-sharing payments for seven years following first commercial sale. In total, the transaction provides the potential to generate more than US$25 million over time, subject to commercial performance.
The sale strengthens PharmaTher’s focus on the development and commercialization of the patented long-acting injectable (“LAI”) ketamine program being advanced under an exclusive evaluation and option-to-license agreement with Oakwood Laboratories, LLC.
“Closing the ANDA sale marks the start of PharmaTher’s next chapter,” said Fabio Chianelli, Chairman and Chief Executive Officer of PharmaTher. “We have converted a legacy generic asset into non-dilutive capital and long-term upside, and we are now fully focused on building a differentiated, long-acting ketamine franchise for neuropsychiatric disorders.”
READ MORE
|
Tilray Brands Announces Implementation of Previously Approved 1-for-10 Reverse Stock Split
Common Stock Expected to Begin Trading on a Split-Adjusted Basis on December 2, 2025
NEW YORK, Nov. 26, 2025 — Tilray Brands, Inc. (“Tilray Brands”, “Tilray” or “the Company”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of the global cannabis, beverage, and wellness industries, today announced that it will implement a one-for-ten reverse stock split of the Company’s common stock (the “Reverse Stock Split”), as previously approved at the special meeting of stockholders held on June 10, 2025.
The Reverse Stock Split is expected to be effective at 4:01 pm Eastern Time on December 1, 2025 (the “Effective Date”) and shares of the Company’s common stock will begin trading on a split-adjusted basis under the same symbol (TLRY) when the markets open on December 2, 2025, with the new CUSIP number of 88688T209.
As previously disclosed, Tilray’s stockholders approved, at a special meeting of stockholders held on June 10, 2025, a proposal authorizing an amendment to the Company’s Fifth Amended and Restated Certificate of Incorporation to effect a reverse stock split of its common stock at a ratio within the range of not less than one-for-ten and not more than one-for-twenty, as set by the Board of Directors.
READ MORE | Optimi Health to Supply MDMA to MAPS Israel’s Clinical Trial for Trauma-Related PTSD
Approved multicenter study sponsored by Sheba Medical Center to compare group and individual MDMA-assisted therapy for 168 patients experiencing trauma-related PTSD
Vancouver, British Columbia-November 26, 2025 – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (“Optimi” or the “Company“), a Canadian manufacturer of pharmaceutical-grade psychedelics, including MDMA and naturally derived psilocybin, has been selected to supply the MDMA capsules for MAPS Israel’s Healing October 7th project, which includes a clinical trial for Post-Traumatic Stress Disorder (PTSD) that has received formal approval from the Israeli Ministry of Health.
The open-label, multicenter, non-inferiority study will evaluate the safety and effectiveness of individual versus group MDMA-assisted therapy for PTSD in patients diagnosed in the context of recent collective trauma. The trial is being conducted as part of MAPS Israel’s Healing October 7th initiative, which supports survivors, veterans, and community-based care.
The study will enroll 168 participants, with initial approval already granted by the Israeli Ministry of Health for the first 20 patients. Each participant will receive three MDMA-assisted therapy sessions supported by Optimi’s GMP 40mg and 60mg MDMA capsules, in accordance with the clinical protocol.
READ MORE |
Cronos Launches Premium Lord Jones Live Resin Fusions™ in Canada
Nov. 25, 2025 — Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), an innovative global cannabinoid company, today announced is expanding its portfolio for its Lord Jones® brand with new innovations designed to enhance its lineup of premium cannabis products in the Canadian market.
The new Lord Jones Live Resin Fusions™ pre-rolls combine top-tier craftsmanship with exceptional cannabis genetics, reflecting the brand’s continued dedication to quality and refinement. The Lord Jones Live Resin Fusions™ are carefully curated, pairing single-sourced dried flower with complementary, terpene-rich pure live resin caviar to deliver a delicious, flavor-forward, and differentiated smoking experience. Designed with an optimal ratio of live resin caviar-to-flower, each 0.5g pre-roll ensures a consistently smooth burn and high potency of 42%+ THC. Every pre-roll is fitted with a reusable ceramic tip, which cools the smoke for an even smoother, elevated experience.
READ MORE |
BELOW ARE THE LINKS TO THE DIRECTORY OF FLORIDA CANNABIS DOCTORS AND
DISPENSARIES IN THE STATE OF FLORIDA |
QUALIFIED PATIENTS
OVER 929,000
AND 734 DISPENSING LOCATIONS |
LATEST OMMU REPORTS FROM OFFICE OF MEDICAL MARIJUANA USE IN THE STATE OF FLORIDA Highlights from
NOVEMBER 28, 2025 Report BY THE NUMBERS
Qualified Patients: (Active ID Card) NOV 28 2025 929,389 NOV 21 2025 929,916
NOV 14 2025 930,384
NOV 07 2025 931,117
OCT 31 2025 931,266
OCT 24 2025 930,628
OCT 17 2025 930,093
Patients Last Week: - 527
Qualified Ordering Physicians: 2,466 New Doctors Last Week: 5 Reporting Period: NOV 21- NOV 27, 2025
Amount of Medical Marijuana Dispensed - (mgs THC) 494,262,826
Amount of Low-THC Cannabis Dispensed - (mgs CBD) 290
Amount of Marijuana in a From for Smoking (oz) 156,725.615
Approved Dispensing Locations: 734 ADDED LAST WEEK - 0 |
UPCOMING MEETING AND CONFERENCES LOOK FOR IN FUTURE ISSUES |
ADVERTISEMENT OPPORTUNITIES
If your goal is to get your business in front of the right people in the cannabis industry or you want to be an integral part of this new and exciting business opportunity, then you need to join with Cannabis News Florida as we help to establish cannabis as a major part of the economy in Florida. Cannabis News Florida is an online publication focusing on both local and national news from leading authorities about the medical and business developments in the medical cannabis industry covering the entire state of Florida.
Join the Cannabis News Florida force online and in print. We offer several marketing options to fit all budgets:
· MMTC PROMOS LISTED IN EACH E-NEWSLETTER
• Directory Listing
• Banner Ads
• Ad Space in the Newspaper
• Feature Articles
• Weekly Newsletters
For further information or to make your ad reservation, please call:561-368-6950 / 954-605-4785 cell charles@cannabisnewsflorida.com
|
|
|